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Few outcome assessments are published from complementary and alternative medicine (CAM) practices. We aimed to describe
patient and practice characteristics of ND care for hypertension (HTN), quantify changes in blood pressure (BP), and evaluate the
proportion achieving control of HTN during care. A retrospective, observational study of ND practice in HTN was performed in
an outpatient clinic in WA State. Eighty-ﬁve charts were abstracted for the ﬁnal analysis. At initiation of care, the mean patient age
was61years,with51%havingstage2HTN,despitecommonuseofanti-hypertensivemedications (47%).Patients withbothstage
1 and stage 2 HTN appeared to improve during care, with stage 2 patients achieving mean reductions of −26mmHg (P<. 0001)
and −11mmHg(P<. 0001)insystolicBP(SBP)anddiastolicBP(DBP),respectively.Theproportionofpatientsachievingcontrol
(<140/90mmHg) in both SBP and DBP was increased signiﬁcantly from 14 to 44% (P<. 033), although the statistical signiﬁcance
was not maintained upon correction for multiple comparisons. BP appears to improve during ND care for HTN, in a high-risk
population. Randomized trials are warranted.
1.Introduction
Hypertension (HTN) is an important, poorly controlled
risk factor for developing cardiovascular disease (CVD)
in the USA, including myocardial infarction and stroke
[1]. Data from the Third National Health and Nutrition
Examination Survey (NHANES) suggest that patients with
uncontrolledHTNhavenearlya2-foldriskofcardiovascular
mortality compared with normotensive adults [2]. The
Seventh Report of the National Committee on Prevention,
Detection, Evaluation and Treatment of High Blood Pressure
(JNC-7) suggests that risk for CVD event doubles with
each 20mmHg increment of systolic blood pressure (SBP),
and each 10mmHg increment of diastolic blood pressure
(DBP),over115/75mmHg[3].Despiteevidenceofincreased
utilization of medical care for HTN, large longitudinal
cohorts suggest that up to 50% of all US patients with HTN
are not at their optimal treatment target [4].
Intensive lifestyle counseling recommendations are
included in most major guidelines for HTN management,
including JNC-7; however, the available evidence suggests
these recommendations are infrequently given to patients
[3, 5]. According to the National Ambulatory Medical Care
Survey, fewer than 50% of patients with HTN received
lifestyle counseling [6]. In contrast, descriptions of naturo-
pathic (ND) practice suggest clinical recommendations by
ND physicians include diet counseling, exercise prescription
and stress management advice for 69–100% of diabetes
patients [7–9].
In Washington State, ND physicians are primary care
providers with a scope of practice that includes nutri-
tional supplementation, herbal medicine, nutrition, exercise,
physical medicine modalities, minor surgery and most
prescription drugs, including all classes of anti-hypertensive
medications. Frequently classiﬁed as “complementary and
alternative medicine (CAM)”, ND medicine is a variant
of healthcare delivery that provides an interesting model
to study the eﬀectiveness of cardiovascular risk factor
reduction because it includes health promotion counseling,
nutritional supplementation and pharmacologic treatment2 Evidence-Based Complementary and Alternative Medicine
options. ND care creates a laboratory for evaluations of
both the eﬀectiveness of health promotion in practice and of
an “integrative” practice model, including CAM plus select
prescription therapy.
Few data are available regarding the eﬀects of CAM
practice in the treatment of HTN; however, national surveys
suggest CAM use in patients with CVD is common. Specif-
ically, data from NHANES 2002 suggests that nutritional
supplement use amongst patients with HTN is common-
place; 62% of respondents used some form of nutritional
supplementation, with multivitamins (40%), antioxidants
(26%) and calcium (27%) being the most common [10].
Practice-based evaluations noted that 58% of patients using
nutritional supplements were simultaneously taking medi-
cations with narrow therapeutic windows including digoxin
and warfarin, reinforcing the need for practice evaluations
of outcomes [11]. ND practice evaluations in type 2 diabetes
have reported mean BP reductions, and recommendations
for nutritional supplementation in 100% of patients [8].
Unfortunately, “whole systems” evaluations of HTN treat-
ment from unique CAM disciplines have not been reported
in the medical literature, leading to the discouragement
of CAM use for HTN by some authors [12]. Here, for
the ﬁrst time, we provide a quantitative evaluation of
“whole practice” ND clinical care for the treatment of HTN,
including a description of nutritional supplementation use
in practice and estimates of change in clinical risk.
2. Methods
I no r d e rt od e s c r i b eN Dp r a c t i c ef o rt h et r e a t m e n to f
HTN, and to estimate possible changes in cardiovascular
risk, we performed a retrospective, observational study of
HTN care in an outpatient ND clinic, the Bastyr Center
for Natural Health, in Seattle, WA. We aimed to describe
the patient population pursuing ND care for HTN, describe
practice characteristics including the delivery of health
promotion counseling and nutritional supplementation, and
estimate the changes in SBP and diastolic DBP including
the proportion of patients who achieve controlled BP during
care. The study was reviewed and approved by institutional
review boards at both Bastyr University and the University of
Washington.
2.1. Case Inclusion and Data Collection. Medical charts were
identiﬁed through clinic scheduling software, searchable by
ICD-9 code, and data were abstracted between December
2006 and June 2007. The analyses included patients meeting
three ap r i o r i -speciﬁed inclusion criteria: (i) an ICD-9
assessment of HTN was made by the ND (i.e., 401.XX–
405.XX), (ii) evidence of at least 6 months of ND care
occurred between 2001 and 2006 and (iii) ND care provided
speciﬁcally for HTN (versus accompanying symptoms or
associated conditions). A 6-month duration of care was
speciﬁed in an attempt to balance bias between using
either too short or too long of an observation period.
Specifying too long of a care period may oversample the
uniquely motivated, whereas too short of a care period may
underestimate eﬀects of a re-iterative care process.
The following data were collected: patient character-
istics including race, gender, age and current anti-HTN
medications; care characteristics including primary versus
adjunctive care, duration of care, presence of “care gaps”
(interval in appointment dates greater than 6 months
apart), and number of visits during the care period; BP
measurements over the duration of care; and character-
istics of treatment recommendations, including lifestyle
counseling (diet and exercise), nutritional supplementation
and the initiation of new anti-hypertensive prescription
medication. “Primary care” (PCP) status was deﬁned as
either the ND being designated on provider contact sheet
as the PCP, or ND provision of annual preventive service
visits. Care characteristics were calculated as the percentage
of patients receiving various recommendations, including
speciﬁc dietary recommendations, exercise prescription and
nutritional supplementation, as well as the percentage of
visits during which these recommendations were given.
2.2.BPMeasurementandDeﬁnitionofControl. BPdatafrom
the patient’s ﬁrst visit was compared with the most recently
available measurement at the time of chart abstraction in
analyses. The statistical signiﬁcance of mean BP changes was
determined using two-tailed, paired t-tests of homogeneity
applied to the diﬀerence between the most recently available
reading, and the baseline reading, with our null hypothesis
being the change in BP was zero between these time points.
These tests were applied to the BP data independent of
stage, and then repeated after stratiﬁcation by stage. Patients
were assigned to stages based on JNC-7 criteria (stage 1
= SBP 140–159mmHg or DBP 90–99mmHg; stage 2 =
SBP≥160mmHgorDBP≥100mmHg)[3].Inaddition,the
proportion of patients in “good BP control” at their ﬁrst visit
was calculated and compared with the proportion in control
at their most recent measurement, using Fisher’s exact test.
“Control” was deﬁned as <140/90mmHg at either point
(baseline versus last observed). In addition, the proportions
of patients in systolic or diastolic control, and the proportion
in systolic and diastolic control, were calculated and com-
pared. Following data abstraction and coding, analyses were
performed on Statacorp STATA for Mac v. 10.0.
3. Results
3.1. Final Study Sample. After applying inclusion criteria to
all records for patients receiving care for HTN between 2001
and 2006 (n = 249), a total of 85 charts were included
for detailed data abstraction. The most common reason
for exclusion was a lack of a 6-month duration of care
(excluded n = 121 or 49% of total); this ﬁnding is consistent
with the high degree of adjunctive ND care use. Baseline
characteristics of this sample population are reported in
Table 1. As expected, baseline SBP was crudely associated
with continuous age (βcrude. = 0.44; 95% CI: 0.17, 0.71,
P = .002), male gender (βcrude = 8.66 (95% CI: 0.08, 17.2)
for male versus female, P = .05) and continuous baseline
diastolic BP (βcrude = 0.61; 95% CI: 0.27, 0.96, P = .001),
but not race (βcrude. = 0.35; 95% CI: − 4.4, 5.1 for Caucasian
versus non-Caucasian, P = .88).Evidence-Based Complementary and Alternative Medicine 3
Table 1: Characteristics of sample population at initial ND visit for
HTN.
Population characteristic (n = 85) Mean (SD)
or n (%)
Age (years) 60.6 (14.9)
Sex
Male 35 (41%)
Female 50 (59%)
Ethnicity
White 45 (53%)
Non-White 12 (14%)
Unknown 28 (33%)
BP (mmHg)
SBP 157.5 (20)
DBP 89.9 (11.8)
BP stages
Stage 1 30 (35%)
Stage 2 43 (51%)
Controlled (<140/90) on anti-HTN medications 12 (14%)
Use of anti-HTN medications at ﬁrst visit 40 (47%)
ND prescribed new anti-HTN medication added
during ND care period 14 (16%)
Total new anti-HTN medication added during ND
period 25 (29%)
3.2. Characteristics of Care Delivery and Treatment Rec-
ommendations. Table 2 summarizes select characteristics of
ND care for HTN. On average, patients attended 8.7 ND
visits over a 13.8 (±8.7 months) care period. Thirty-two
patients (37.6%) had evidence of at least one 6-month gap
in their ND care. ND care remained mostly adjunctive
(76.5%); however, 23.5% of patients appeared to utilize
ND care as primary care. The provision of diet, exercise
and preventive counseling was common during ND care
for HTN. Eighty-three patients (97.6%) received dietary
counseling, reiterated over 54.8% of all visits. Fifty-eight
patients (68.2%) received counseling to increase physical
activity, reiterated over 33% of all visits. Speciﬁc dietary
recommendations are also summarized in Table 2.I nn e a r l y
all cases, patient educational handouts were evident in the
medical record.
As shown in Table 2, the prescribing of nutritional
supplementation was also typical in ND treatment of
HTN; all patients were recommended to take nutritional
supplements.Omega-3oilfromﬁshwasthemostcommonly
recommended supplement (55.3%), followed by “Combo
1”, a commercial botanical/mineral combination containing
Rauwolﬁa, Arjuna, Convolvulus, Tribulus and magnesium
aspartate (50.6%); magnesium (43.5%); CoQ10 (38.8%);
Crataegus (hawthorne) (32.9%); “Combo 2” containing
vitamin B6, magnesium citrate-malate, Allium sativa, Tarax-
acum, Rauwolﬁa, Crataegus, Leonurus, Passiﬂora,R e s v e r a t r o l
and CoQ10 (12.9%); and potassium (8.2%). Concurrent
prescribing of these supplements was common (42%). Many
Table 2: Care characteristics of ND care for HTN.
Care characteristic Mean (mode, median
and IQR) or n (%)
Number of visits 8.7 (4,7,4)
Duration of care
(months) 13.8 (7,12,8)
Presence of care “Gap” 32 (37.6%)
Primary care 20 (23.5%)
Category of health
promotion advice n (%) receiving advice
Diet 83 (97.6%)
Exercise 58 (68.2%)
Alcohol 48 (56.5%)
Tobacco 40 (47.1%)
Speciﬁc dietary advice n (%) receiving advice
Increase fruit and
vegetable intake 71 (83.5%)
Increase
legumes/beans/nuts/whole
grains
43 (50.6%)
Reduce dietary sodium 36 (42.3%)
Increase dietary ﬁber 31 (36.5%)
Increase ﬁsh intake 17 (20%)
Adopt the “DASH” diet 16 (18.8%)
Adopt the
“Mediterranean” diet 3 (3.5%)
Nutritional
supplementation
n (%) receiving
recommendation
Omega-3 Oils from Fish 47 (55.3%)
“Combo 1” 43 (50.6%)
Magnesium 37 (43.5%)
Coenzyme Q10 33 (38.8%)
Crataegus oxycanthus
(Hawthorne) 28 (32.9%)
“Combo 2” 11 (12.9%)
Potassium 7 (8.2%)
IQR: Inter-quartile range.
other nutritional and botanical supplements were recom-
mended; however, these products were recommended to
<5% of patients. Figure 1 presents the hypothetical rationale
for elements of health promotion counseling, as well as for
select nutritional and herbal medicines [13–19].
3.3. Observed Changes in BP. Figures 2(a) and 2(b) detail
the average change in SBP and DBP during the course
of ND care, combined and by baseline stage. As the
ﬁgures demonstrate, BP reductions were sizable, statistically
signiﬁcant based on t-tests for homogeneity and positively
correlated to stage at baseline. Patients with both stage 1
and stage 2 HTN appeared to improve during care, with
stage 2 patients achieving mean reductions of −26mmHg
(P<. 0001) and −11mmHg (P<. 0001) in SBP and DBP,
respectively.4 Evidence-Based Complementary and Alternative Medicine
Dietary change (97.6%)=
↓ inﬂammation and
Na-induced ﬂuid retention
Physical activity (68.2%)=
↑ ﬂow mediated dilation and
↓ resting heart rate
Omega-3 fatty acids (55.3%)=
↑ cell membrane function and
↓ inﬂammation
Rauwolﬁa (50.6%)=
Magnesium (43.5%)=
↑ smooth muscle relaxation
CoQ10 (38.8%)=
↑ myocardial ATP
Haw-thorne
(32.9%)=
↑ AOX and O2
use
↓ sympathetic tone
Figure 1: Hypothetical model for select elements of naturopathic treatment of hypertension. Values in parentheses indicate the percentage
of patients receiving this recommendation. Citations for the hypothetical actions are included in the main text. AOX, antioxidant action;
ATP, adenosine triphosphate; Na, sodium; O2, oxygen.
Table 3: Patients with controlled BP during ND care compared with baseline.
“Control” deﬁnition n (%) at baseline n (%) at last observation P-valuea
SBP<140mmHg 14 (16.5%) 43 (50.6%) .038
DBP<90mmHg 35 (41%) 61 (71.8%) .026
Combined systolic and diastolic control
Neither SBP nor DBP<140/90mmHg 48 (56.5%) 18 (21.2%) .033
Either SBP or DBP<140/90mmHg 25 (29.4%) 30 (35.3%)
Both SBP and DBP<140/90mmHg 12 (14.2%) 37 (43.5%)
aFisher’s exact test.
Table 3 compares the proportion of patients in good
BP “control” at their ﬁrst visit, compared with control at
their most recent measurement during ND care. We found
a strong trend for both an increased proportion of patients
in either systolic or diastolic control, and an increased
proportion in both diastolic and systolic control. Notably,
only 14% were in SBP and DBP control at baseline, versus
44% at the last available measurement. These ﬁndings, in
combination with sizable average SBP and DBP reductions
in both stages, suggest that clinically meaningful reductions
are achieved during ND care.
Given the marginal statistical signiﬁcance of several of
the results, the statistical signiﬁcance would not hold up
to a Bonferroni-corrected signiﬁcance threshold (n = 9;
Pcorr. <. 0056); however, mean reductions for all categories,
except stage 1 SBP, would hold up this corrected signiﬁcance
threshold.
4. Discussion
The results of this study suggest that BP is signiﬁcantly
reduced during ND care and the reductions appear clinically
meaningful (−16.1mmHg mean reduction in SBP, P<. 0001
and −7.4mmHg mean reduction in DBP, P<. 0001). Both
severe (stage 2) and moderate (stage 1) HTN appear to
improve. These ﬁndings compare to recent meta-analyses
of typical reductions in BP from pharmaceutical anti-HTN
medicationsinwhichmeanreductionsinSBPof −15mmHg
are seen, on average, per class of medications [20]. Forty-
four percent of patients achieved new BP control during NDEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Mean changes in (a) systolic blood pressure and (b) diastolic blood pressure observed during ND care. Last observed BP—baseline
BP, that is, negative values are reductions. Paired two-sided t-tests for homogeneity, H0 = change = 0. Bold indicates statistical signiﬁcance
after correction for multiple comparisons.
care. Notably, the proportion of patients in both systolic and
diastolic control to <140/90 tripled from 14.2 to 43.5%, or an
increase of 29.3%. This ﬁnding compares to meta-analysis of
63 trials of primary care HTN quality improvement in which
the increase in the proportions of patients reaching SBP
and DBP targets were 16.2% (interquartile range 10.3–32.2)
and 6.0% (interquartile range 1.5–17.5), respectively [21].
Despite not holding up to a corrected signiﬁcance threshold,
the trend is strong and the observed point estimates are
clinically meaningful.
In addition, our study suggests that the dietary advice
givenbyNDphysiciansisevidencebased.Recommendations
to increase dietary ﬁsh (20%), or take ﬁsh oil (55.3%), are
supported by the American Heart Association; however,
literature suggests that this recommendation is infrequently
given in standard primary care (17%) [22, 23]. Additional
recommendations include sodium reduction and increasing
wholegrains,legumes,ﬁsh,fruitandvegetableconsumption.
When adopted, the dietary recommendations have the
potential to reduce patient risk for multiple chronic diseases,
not just HTN [24].
Supporting the notion that ND care is a laboratory for
studies of the delivery of health promotion counseling in
clinical practice, we observed recommendations for dietary
change and increased physical activity were commonplace
in ND care for HTN (Table 2) and may be responsible
for some, or all, of the observed changes. The observed
reductions are comparable to the contribution of lifestyle6 Evidence-Based Complementary and Alternative Medicine
modiﬁcation on BP reductions reported in JNC-7 guidelines
[3]. Estimates for the delivery of health promotion counsel-
ing to at risk patients (68.2–97.6%) exceed estimates from
routine allopathic care and are consistent with American
Heart Association and the US Preventive Services Task Force
(USPSTF) guidelines [5, 6, 25].
This study has several limitations. While the observed
changes are concurrent with ND care, causation cannot
be determined from observational data. This study lacks a
natural history control group; however, advancing age and
higher baseline BP were both predictors of not reaching BP
control in the Framingham cohort, suggesting elevated BP
typically does not self-resolve in a population of advancing
age[26].Ourstudymaynothaveaccountedforallhealthcare
services utilized; it remains unknown whether speciﬁc ND
treatments, including supplements, contributed to the BP
reductions or if other recommendations, including medi-
cation adherence reminders or the care of other providers,
resulted in these changes. In the 29% of patients receiving
advice to take new anti-HTN medications, subsequent mul-
tivariate logistic regression analyses showed no association
with either baseline or new anti-HTN medications and odds
of control (data not reported here). Also the population
under study was self-selecting ND care, with a minimum
of 6 months of care, and therefore these patients are likely
exceptionally motivated for health improvement. Although
multipletestingincreasedtheprobabilityofatype1error,we
havediscussedtheresultsinrelationtocorrectedsigniﬁcance
thresholds. Finally, despite its importance in predicting risk
for CVD and CVD-related mortality, BP remains a surrogate
outcome measure, and therefore the impact of the observed
reductions on clinical cardiovascular events or other health
outcomes cannot be determined [1, 27].
The results of our study, although preliminary, have
important clinical implications. Speciﬁcally, risk reduction
from HTN appears to occur during ND care. The observed
tripling of the proportion of patients in HTN control
to <140/90mmHg is both encouraging and provocative
especially given the advanced age and signiﬁcant proportion
with stage 2 HTN. It has been reported that patients who
use CAM trend toward lower adherence to medications and
thereforeourstudyoﬀerssomereassurancesthatNDsappear
toengageonHTNclinically,oﬀerevidence-basedhealthpro-
motion counseling and prescribe anti-HTN medications as
needed to reduce risk [28]. The observed greater reductions
inthosewithstage2HTNatthebeginningofcare,compared
with those with stage 1, is also reassuring and suggest ND
treatment is either eﬀective at various risk stages and/or
that treatment is tailored depending on risk at presentation.
Nutritional supplementation was used routinely in patients
with HTN, which despite hypothetical eﬀects (see Figure 1)
have limited data supporting clinical use. Exceptions include
omega-3 fatty acids from ﬁsh (for which two meta-analyses
s u g g e s tb e n e ﬁ ti nH T N )a n dC o Q 1 0( w h i c hh a sb e e n
recognized as having “sound” evidence) [29–34].
Future studies of the impact of ND and other CAM
services on HTN and composite cardiovascular risk should
include prospective, observational evaluations of multiple
ND practices, allowing for multivariate analyses in larger
sample sizes to reduce the risk of type 2 error; these
evaluations could be best accomplished with practice-based
research networks initiated through academic and large
group ND practices. Given the costs and unknown medica-
tion interactions of supplementation for HTN, prospective
monitoring and factorial clinical trials on the use of supple-
ment combinations should also be pursued.
5. Conclusion
Reductions in BP were observed during care by ND physi-
cians; however, the care characteristics responsible for the
changes could not be determined from this analysis. ND
practice appears to have several positive qualities from a
public health perspective, including clinical engagement on
CVD risk factor reduction, a high prevalence of guideline
recommended lifestyle counseling and the use of evidence-
based dietary recommendations.
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